While it’s unconscionable that hedge fund pharmaceutical companies like Turing and Retrophin purchase treatments and suddenly raise prices, the current model in which drug companies raise prices year after year is just as bad for patients – and, frankly, unsustainable for our entire health care system. Read More
Today the National Coalition on Health Care Action Fund announced that the American Academy of Neurology (AAN) has officially joined the coalition’s Campaign for Sustainable Rx Pricing. The American Academy of Neurology represents 30,000 members and is dedicated to promoting the highest quality patient-centered neurologic care. Read More
"Companies are buying decades-old prescription drugs and jacking up prices on vulnerable patients. It’s unconscionable. We need more transparency and competition in the prescription drug market to protect Americans from this appalling practice.” Read More
"Recently, the FDA took an important first step in acknowledging the need to introduce more competition by prioritizing generic applications where there is no competition. This effort will give patients better access to affordable treatments," said John Rother, executive director of the Campaign for Sustainable Rx Pricing. Read More
Today the National Coalition of Health Care announced that AARP has officially joined the coalition’s Campaign for Sustainable Rx Pricing. AARP is a nonprofit, nonpartisan organization, with a membership of nearly 38 million Americans and shares the Campaign’s goal of finding market-based solutions to reverse the trend of high and rising prescription drug prices. Read More
Seven presidential candidates are still in the race heading into Super Tuesday and all of them are talking about rising prescription drug prices. While they differ in their solutions to this epidemic, candidates on both sides of the aisle agree that drug prices are rising at an unsustainable rate. Read More
“Today’s AARP report provides new evidence that drug companies are raising prescription drug prices on patients indiscriminately. Specialty and branded drugs alike are going up six times faster than inflation. The exorbitant increases make health care more expensive for families, taxpayers, and job creators and put a major strain on federal and state governments. It's going to take market-based policy solutions to deal with this unsustainable trend.” Read More
Over the next few days, Nevadans of both political parties will caucus to choose their presidential nominee — the Democrats on Saturday, and Republicans on Tuesday in the first-of-the-West caucuses. As candidates travel the state in an effort to woo potential caucus-goers, there will be many public policy disagreements. Read More
Crippling drug prices have quickly become one of the hottest topics in health care. Consumers, patients, state budgets and public programs are feeling the burden, and reports show that we’re just getting started. Read More
"Today the president took an important step in his FY 2017 Budget to support transparency in the market and provide new information to consumers. CSRxP welcomes this step and encourages Congress and the Administration to take action to make prescription drugs affordable for all Americans.” Read More
“Prescription drug cost hikes are not limited to companies run by people like Martin Shkreli; they are commonplace in the pharmaceutical industry. This issue transcends political party lines because consumers, patients, and public programs across the country simply cannot afford higher prices for medication." Read More
Daraprim's price hike was outrageous. But prices on prescriptions that are more widely used also continue to climb. Since the beginning of January, pharmaceutical giant Pfizer has raised prices on more than 100 of its prescription drugs, according to Reuters. Some of those drugs, like medicines used to help treat symptoms of menopause or combat seizures, went up by more than 20 percent. What’s more, Pfizer did not reduce the price of any prescriptions. Read More